Week In Review 6 November 2020

US equity indexes rose strongly this week: DJIA +6.9%, S&P 500 +7.3%, and NASDAQ +9.0%.

At the time of writing on Saturday, major news networks are calling the US Presidential Election for VP Biden. However, during the past week post- US Election Day and while markets were open, the US Presidential race had not been called. US equities rose despite this uncertainty, perhaps on a combination of getting through the event itself and hope that a winner would be announced soon. Control of the Senate has not been settled yet with key seats in Georgia headed for a run-off.  

Turning to central banks, Senior Advisor Chris Marsh comments on the Bank of England policy meeting: “The BoE beat expectations by expanding government bond purchases by GBP150BN (exp. GBP100BN) to run from Jan. 2021 until end-2021. These purchases will occur after the remaining GBP100BN from the existing program is exhausted and will continue at roughly the current pace but slow into end-2021. There was no mention of negative rates in the press release on which the Bank is waiting for responses to questionnaires on financial sector preparedness by Nov. 12th.”
On BoE Forecasts: “The GDP forecast for 2020 was revised down to -11% (from -9.5%), and 2021 to +7.25% (from +9%). The Bank assumes a successful Brexit negotiation, but factor in for the first time a drag in early-2021 from the transition. Real GDP does not reach end-2019 levels until mid-2023, acknowledging the lingering economic effect from COVID.”
On Chancellor Sunak and the wage furlough scheme: Chris notes, “Following the BoE’s announcement, Chancellor Sunak announced an extension of the wage furlough scheme through end-March 2021, scrapping the previous, less generous jobs support scheme that was due to begin in December. In addition, workers made redundant after Sept 23rd can be rehired and placed on furlough. The next OBR read on the UK fiscal position is due by end-November.”


Ahead Next Week:  Select economic releases: Sunday, Nov 8: China Composite PMI. Monday, Nov 9: Germany Trade Balance and Current Account (Sep), Australia NAB Business Confidence (Oct), China CPI (Oct). Tuesday, Nov 10: UK Claimant Count Change (Oct), German ZEW Sentiment (Nov), EZ ZEW Sentiment, Australia Westpac Consumer Sentiment (Nov), RBNZ Monetary Policy Decision. Wednesday, Nov 11: Japan Foreign Investment Stocks/Bond Buying, ECB Forum on Central Banking (schedule here). Thursday, Nov 12:  UK GDP (Q3), UK Goods Trade Balance (Sep),  German CPI (Oct), ECB Forum on Central Banking – will feature a policy panel Thursday with BoE’s Bailey, ECB’s Lagarde, and Fed’s Powell.  US Initial Jobless claims, US Core CPI (Oct), Friday, Nov 13: EZ GDP (Q3), EZ Trade Balance (Sep), US U of Michigan  Consumer Sentiment (Nov). 

USD Comment

With US equity indexes up on the week, USD broadly weakened. However, given the strong rise in the S&P 500, it was surprising that USD was not weaker than it was. DXY Index started the week at 94.26 and ended at 92.23 – around the week’s low. 92.00 is support. Higher beta currencies NOK, SEK, AUD, NZD, MXN benefitted from the equity rally. EURUSD range: 1.1614-1.1885. GBPUSD range: 1.2860-1.3171 (Friday high). As the week wore on with US swing states counting votes, JPY strengthened falling sub-104.00 to a low of 103.21. As it is the start of the month, you can see our USD November Seasonality from our proprietary FX factor model here USD is weaker in November vs G10 FX.



Coronavirus Update

US: The US 3rd wave continues to broaden and accelerate with new cases accelerating past 100k per day in recent days and fatalities rising to more than 1500 on Thursday.  While the most severe outbreaks remain in the Dakotas, there are signs that we may again need to keep an eye on major population centers where hospital pressure is likely to be the key driver of policy-tightening and self-policing. Here is the heatmap of US states’ trend daily growth in confirmed coronavirus cases.


Our analysis suggests there is a possible link between temperature and case growth in the US. The overall sense is that with temperatures dropping, it is likely that Rt in the US will rise, increasing the likelihood for greater case growth in coming weeks. We have been seeing this in our daily tracking in the Midwest and increasingly the Northeast. Additionally, we can see that self-policing plays a role in bringing Rt down, but the lesson from Europe is that stricter methods (though not necessarily nation-wide lockdowns) are critical to setting a peak in cases.



International:  As we track case momentum in Europe, we observe that Western Europe is on a path that starts to look better.  Specifically, the UK continues to improve and Ireland is seeing solid fall in case growth. Italy’s momentum is better recently (but still accelerating). France is a bit better though the turn is shaky there.  In Eastern Europe, Czech Republic still looks good, while Poland also showing a bit better (though still accelerating) momentum. Hungary’s situation is more tenuous. You can see our grid of week-on-week growth of new cases (not cumulative cases) to get a fast read on whether policy measures are starting to work here


As cases continue to surge in Europe, our deaths forecast is now over 3,000 per day by late November, and the realized deaths are surpassing the US for the first time in many months (as projected over the last few weeks). There are signs in recent days (driven by decelerating case growth) that the trajectory of expected fatalities will start to flatten by early December.




Founder Jens Nordvig appeared on CNBC  at around 5:30pm EST on Election night and discussed the outlook for USD and the importance of the Senate outcome.

Head of Asia Pacific Grant Wilson appeared on Auz Bis at around 9pm EST on US Election night to discuss results so far and what could be in store ahead for markets. 


For more information on our Macro Strategy, Global Flow Analytics, and/or Exante Data API, institutions please reach out to us here.

Exante Data © 2020. All rights reserved. Personal Data Usage Policy

This site is provided for informational purposes only.  The information included in this site should not be used as the sole basis for making a decision as to whether or not to invest in any particular security. In making an investment decision, you must rely on your own examination of the securities and the terms of the offering. You should not construe the contents of these materials as legal, tax, investment or other advice, or a recommendation to purchase or sell any particular security.

The information included in this site is based upon information reasonably available to Exante as of the date noted herein. Furthermore, the information included in this site has been obtained from sources that Exante believes to be reliable; however, these sources cannot be guaranteed as to their accuracy or completeness. Information contained in this site does not purport to be complete, nor does Exante undertake any duty to update the information set forth herein. No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information contained herein, by Exante, its members, partners or employees, and no liability is accepted by such persons for the accuracy or completeness of any such information.

This site contains certain “forward-looking statements,” which may be identified by the use of such words as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” “potential,” “outlook,” “forecast,” “plan” and other similar terms. Examples of forward-looking statements include, but are not limited to, estimates with respect to financial condition, results of operations, and success or lack of success of certain investment strategy. All are subject to various factors, including, but not limited to, general and local economic conditions, changing levels of competition within certain industries and markets, changes in interest rates, changes in legislation or regulation, and other economic, competitive, governmental, regulatory and technological factors affecting the operations of the companies identified herein, any or all of which could cause actual results to differ materially from projected results.

Get more information about Exante Data
Get Ahead With Our Updates with Our Exante Newsletter